Strategies to inhibit FGFR4 V550L-driven rhabdomyosarcoma

Elisa Fiorito(Oslo University Hospital), Jørgen Wesche(Oslo University Hospital)

British Journal of Cancer

September 12, 2022

10.1038/s41416-022-01973-6

Cited by 9

Related Papers

Clathrin- and Dynamin-Independent Endocytosis of FGFR3 – Implications for Signalling

|PLoS ONE|2011|47

Protein Tyrosine Phosphatase Receptor Type G (PTPRG) Controls Fibroblast Growth Factor Receptor (FGFR) 1 Activity and Influences Sensitivity to FGFR Kinase Inhibitors

|Molecular & Cellular Proteomics|2018|40

Preparation and Characterization of an Engineered FGF1 Conjugated to <sup>161</sup>Tb for Targeting of FGFRs

|ACS Omega|2025|2